Schedule of investments
Delaware Healthcare Fund | December 31, 2022 (Unaudited) |
Number of shares | Value (US $) | ||
Common Stocks — 99.92%♦ | |||
Biotechnology — 31.60% | |||
ACADIA Pharmaceuticals † | 160,000 | $ 2,547,200 | |
Alkermes † | 423,142 | 11,056,701 | |
Allogene Therapeutics † | 146,779 | 923,240 | |
Alnylam Pharmaceuticals † | 41,000 | 9,743,650 | |
Altimmune † | 208,685 | 3,432,868 | |
Amarin ADR † | 190,000 | 229,900 | |
AnaptysBio † | 93,732 | 2,904,755 | |
Arcus Biosciences † | 379,100 | 7,839,788 | |
Atea Pharmaceuticals † | 70,000 | 336,700 | |
Athenex † | 70,000 | 10,325 | |
BioMarin Pharmaceutical † | 124,000 | 12,832,760 | |
BioNTech ADR | 18,000 | 2,703,960 | |
Cellectis ADR † | 226,875 | 476,438 | |
Clovis Oncology † | 250,200 | 13,198 | |
Cogent Biosciences † | 230,000 | 2,658,800 | |
Coherus Biosciences † | 430,000 | 3,405,600 | |
Compugen † | 852,941 | 610,450 | |
Day One Biopharmaceuticals † | 110,000 | 2,367,200 | |
Dynavax Technologies † | 760,000 | 8,086,400 | |
Exact Sciences † | 96,353 | 4,770,437 | |
Fortress Biotech † | 100,000 | 65,500 | |
Galmed Pharmaceuticals † | 306,010 | 153,005 | |
Incyte † | 80,000 | 6,425,600 | |
Intellia Therapeutics † | 20,000 | 697,800 | |
Intercept Pharmaceuticals † | 27,000 | 333,990 | |
Karyopharm Therapeutics † | 380,000 | 1,292,000 | |
Landos Biopharma † | 147,182 | 73,606 | |
MacroGenics † | 420,000 | 2,818,200 | |
Madrigal Pharmaceuticals † | 28,500 | 8,272,125 | |
MEI Pharma † | 600,000 | 146,160 | |
Mersana Therapeutics † | 150,000 | 879,000 | |
Mirati Therapeutics † | 60,000 | 2,718,600 | |
Moderna † | 18,000 | 3,233,160 | |
MorphoSys † | 300,000 | 4,242,193 | |
Mustang Bio † | 120,000 | 47,388 | |
Myriad Genetics † | 135,000 | 1,958,850 | |
Nektar Therapeutics † | 256,385 | 579,430 | |
Neurocrine Biosciences † | 110,000 | 13,138,400 | |
NextCure † | 150,000 | 211,500 | |
ProQR Therapeutics † | 620,000 | 2,294,000 | |
Provention Bio † | 70,000 | 739,900 |
NQ-G4 [12/22] 2/23 (2741231) 1
Schedule of investments
Delaware Healthcare Fund (Unaudited)
Number of shares | Value (US $) | ||
Common Stocks♦ (continued) | |||
Biotechnology (continued) | |||
Puma Biotechnology † | 61,255 | $ 259,109 | |
Regeneron Pharmaceuticals † | 90,000 | 64,934,100 | |
REGENXBIO † | 149,000 | 3,379,320 | |
Rigel Pharmaceuticals † | 1,600,000 | 2,400,000 | |
Rocket Pharmaceuticals † | 58,000 | 1,135,060 | |
Roivant Sciences † | 338,181 | 2,702,066 | |
Sangamo Therapeutics † | 400,000 | 1,256,000 | |
Sarepta Therapeutics † | 13,000 | 1,684,540 | |
Seagen † | 80,000 | 10,280,800 | |
Sio Gene Therapies † | 64,171 | 27,914 | |
Surface Oncology † | 350,000 | 287,000 | |
Syndax Pharmaceuticals † | 180,000 | 4,581,000 | |
Tarsus Pharmaceuticals † | 172,908 | 2,534,831 | |
Theravance Biopharma † | 208,783 | 2,342,545 | |
Ultragenyx Pharmaceutical † | 70,000 | 3,243,100 | |
uniQure † | 706,166 | 16,008,783 | |
United Therapeutics † | 80,000 | 22,247,200 | |
Vertex Pharmaceuticals † | 25,000 | 7,219,500 | |
Viking Therapeutics † | 330,100 | 3,102,940 | |
Voyager Therapeutics † | 5,700 | 34,770 | |
WaVe Life Sciences † | 81,955 | 573,685 | |
Xencor † | 129,191 | 3,364,134 | |
XOMA † | 3,466 | 63,774 | |
Yumanity Therapeutics = | 750,000 | 0 | |
280,932,948 | |||
Blue Chip Medical Products — 43.91% | |||
AbbVie | 226,559 | 36,614,200 | |
Amgen | 246,964 | 64,862,625 | |
AstraZeneca | 131,243 | 17,799,177 | |
Biogen † | 45,000 | 12,461,400 | |
Boston Scientific † | 380,000 | 17,582,600 | |
Chugai Pharmaceutical | 700,000 | 17,964,035 | |
Eli Lilly & Co. | 130,000 | 47,559,200 | |
Euroapi † | 8,695 | 128,910 | |
Gilead Sciences | 195,000 | 16,740,750 | |
Haleon † | 313,421 | 1,240,363 | |
Johnson & Johnson | 100,000 | 17,665,000 | |
Merck & Co. | 295,000 | 32,730,250 | |
Organon & Co. | 29,500 | 823,935 | |
Pfizer | 604,600 | 30,979,704 | |
Roche Holding | 80,000 | 25,133,834 |
2 NQ-G4 [12/22] 2/23 (2741231)
(Unaudited)
Number of shares | Value (US $) | ||
Common Stocks♦ (continued) | |||
Blue Chip Medical Products (continued) | |||
Sanofi | 200,000 | $ 19,233,846 | |
Sanofi ADR | 225,000 | 10,896,750 | |
Stryker | 15,000 | 3,667,350 | |
UCB | 76,000 | 5,984,415 | |
Zimmer Biomet Holdings | 80,000 | 10,200,000 | |
390,268,344 | |||
Healthcare Services — 14.10% | |||
CVS Health | 100,000 | 9,319,000 | |
Elevance Health | 87,500 | 44,884,875 | |
Quest Diagnostics | 48,000 | 7,509,120 | |
UnitedHealth Group | 120,000 | 63,621,600 | |
125,334,595 | |||
Other — 0.75% | |||
Cia de Minas Buenaventura ADR | 66,353 | 494,330 | |
Fannie Mae † | 1,300,000 | 459,420 | |
Federal Home Loan Mortgage † | 1,050,000 | 370,965 | |
Sohu.com ADR † | 390,722 | 5,356,798 | |
6,681,513 | |||
Small- / Mid-Cap Medical Products — 9.56% | |||
Halozyme Therapeutics † | 230,000 | 13,087,000 | |
Illumina † | 100,000 | 20,220,000 | |
InnoCare Pharma 144A #, † | 17,000 | 29,708 | |
Inspire Medical Systems † | 30,000 | 7,556,400 | |
Intra-Cellular Therapies † | 450,000 | 23,814,000 | |
Perrigo | 210,000 | 7,158,900 | |
Viatris | 1,170,018 | 13,022,300 | |
Zimvie † | 8,000 | 74,720 | |
84,963,028 | |||
Total Common Stocks (cost $648,637,680) | 888,180,428 | ||
NQ-G4 [12/22] 2/23 (2741231) 3
Schedule of investments
Delaware Healthcare Fund (Unaudited)
Number of shares | Value (US $) | ||
Rights — 0.00% | |||
Ambit Bioscience = | 76,500 | $ 0 | |
Total Rights (cost $0) | 0 | ||
Total Value of Securities—99.92% (cost $648,637,680) | 888,180,428 | ||
Receivables and Other Assets Net of Liabilities—0.08% | 690,849 | ||
Net Assets Applicable to 35,277,375 Shares Outstanding—100.00% | $888,871,277 |
♦ | Narrow industries are utilized for compliance purposes for concentration whereas broad sectors are used for financial reporting. |
† | Non-income producing security. |
= | The value of this security was determined using significant unobservable inputs and is reported as a Level 3 security. |
# | Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. At December 31, 2022, the aggregate value of Rule 144A securities was $29,708, which represents 0.00% of the Fund's net assets. |
Foreign Currency Exchange Contracts | ||||||||||
Counterparty | Currency to Receive (Deliver) | In Exchange For | Settlement Date | Unrealized Depreciation | ||||||
BNYM | GBP | (3,612,296) | USD | 4,356,417 | 1/3/23 | $(11,131) |
The use of foreign currency exchange contracts involves elements of market risk and risks in excess of the amounts disclosed in the financial statements. The foreign currency exchange contract presented above represent the Fund's total exposure in such contracts, whereas only the net unrealized appreciation (depreciation) is reflected in the Fund's net assets.
Summary of abbreviations: |
ADR – American Depositary Receipt |
BNYM – Bank of New York Mellon |
Summary of currencies: |
GBP – British Pound Sterling |
USD – US Dollar |
4 NQ-G4 [12/22] 2/23 (2741231)